Tiny study probes bone changes in myeloma patients on common drug
NCT ID NCT04111809
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times
Summary
This study aimed to track four markers of bone turnover in the blood and urine of multiple myeloma patients receiving intravenous bisphosphonates, a standard bone-strengthening treatment. Only 3 patients were enrolled before the study was terminated, so results are very limited. The goal was to understand how these markers change over 12 months and how they relate to medication doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker Hospital, Adult haematology department
Paris, 75015, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.